Page last updated: 2024-08-26

deoxypyridinoline and trelstar

deoxypyridinoline has been researched along with trelstar in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Borderie, D; Cherruau, B; Dougados, M; Ekindjian, OG; Roux, C	1
Anastasi, G; Atteritano, M; Catalano, A; Frisina, N; Gaudio, A; Lasco, A; Melloni, D; Morabito, N; Trifiletti, A	1
Aharoni, D; Assa, A; Bistritzer, T; Mor, A; Rachmiel, M; Weiss, M	1

Trials

2 trial(s) available for deoxypyridinoline and trelstar

Article	Year
Biochemical markers as predictors of bone mineral density changes after GnRH agonist treatment. Calcified tissue international, 1998, Volume: 62, Issue:1 Topics: Adult; Alkaline Phosphatase; Amenorrhea; Amino Acids; Biomarkers; Bone Density; Calcium; Cohort Studies; Collagen; Double-Blind Method; Endometriosis; Female; Gonadotropin-Releasing Hormone; Humans; Hydroxyproline; Luteolytic Agents; Menstruation; Osteocalcin; Parathyroid Hormone; Time Factors; Triptorelin Pamoate	1998
Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:11 Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Bone and Bones; Bone Density; Calcium; Cholecalciferol; Diphosphonates; Humans; Male; Osteoporosis; Prostatic Neoplasms; Time Factors; Triptorelin Pamoate	2004

Article

Year

Biochemical markers as predictors of bone mineral density changes after GnRH agonist treatment.

Calcified tissue international, 1998, Volume: 62, Issue:1

Topics: Adult; Alkaline Phosphatase; Amenorrhea; Amino Acids; Biomarkers; Bone Density; Calcium; Cohort Studies; Collagen; Double-Blind Method; Endometriosis; Female; Gonadotropin-Releasing Hormone; Humans; Hydroxyproline; Luteolytic Agents; Menstruation; Osteocalcin; Parathyroid Hormone; Time Factors; Triptorelin Pamoate

1998

Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:11

Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Bone and Bones; Bone Density; Calcium; Cholecalciferol; Diphosphonates; Humans; Male; Osteoporosis; Prostatic Neoplasms; Time Factors; Triptorelin Pamoate

2004

Other Studies

1 other study(ies) available for deoxypyridinoline and trelstar

Article	Year
Evaluation of bone density in girls with precocious and early puberty during treatment with GnRH agonist. Journal of pediatric endocrinology & metabolism : JPEM, 2011, Volume: 24, Issue:7-8 Topics: Alkaline Phosphatase; Amino Acids; Biomarkers; Bone and Bones; Bone Density; Bone Development; Bone Resorption; Child; Child Development; Child, Preschool; Cohort Studies; Female; Gonadotropin-Releasing Hormone; Humans; Longitudinal Studies; Mechanical Phenomena; Prospective Studies; Puberty, Precocious; Severity of Illness Index; Triptorelin Pamoate; Ultrasonics	2011

Article

Year

Evaluation of bone density in girls with precocious and early puberty during treatment with GnRH agonist.

Journal of pediatric endocrinology & metabolism : JPEM, 2011, Volume: 24, Issue:7-8

Topics: Alkaline Phosphatase; Amino Acids; Biomarkers; Bone and Bones; Bone Density; Bone Development; Bone Resorption; Child; Child Development; Child, Preschool; Cohort Studies; Female; Gonadotropin-Releasing Hormone; Humans; Longitudinal Studies; Mechanical Phenomena; Prospective Studies; Puberty, Precocious; Severity of Illness Index; Triptorelin Pamoate; Ultrasonics

2011